2021 Annual Meeting - Challenging Cases in Cervix Cancer
This session will present challenging cases of women with cervix cancer, either due to poorly studied disease subsets (e.g. paraortic nodal disease management and nodal recurrent disease) , newer advances in standard intracavitary brachytherapy( eg hybrid brachytherapy indications and implementation), technically challenging distributions of disease (e.g. IIIA and IVA cervix cancer needing complex interstitial brachytherapy) or newly controversial subjects in when and how radiation therapy should be used and integrated with systemic therapy (e.g. oligometastatic and oligoprogressive recurrent cervix cancer). Topics of particular interest will be how to integrate SAbR with targeted therapy for cervix cancer and use of complex image guided interstitial brachytherapy for locally advanced cervical cancer. The organizers will solicit cases from social media (Mednet, chartrounds RO Hub) to engage attendees more thoroughly before, during, and after the session. A significant amount of time will also be spent in session to engage the audience for cases from their practice that may be helpful for the rest of the attendees to hear.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, surgeons, nurses, radiation therapists, radiation dosimetrists, radiation physicists and medical oncologists.
Upon completion of this activity, participants should be able to:
- Explain the rationale and choice for radiation therapy in cervix cancer with extensive nodal disease.
- Determine the best brachytherapy treatment options for assymetric large primary cervical cancers and choice of hybrid brachytherapy technique AND image-based complex interstitial brachytherapy approach for Stage IIIA and IV A cervix cancer.
- Determine the ideal approach for integrating radiation and systemic therapy for cervix cancer cancer.
- Kevin Albuquerque, MD, Department of Radiation Oncology, University of Texas Southwestern Medical Center receives compensation from ACR, ARRT, ASCO, and AstraZeneca.
- Hina Saeed, MD, Department of Radiation Oncology, Medical College of Wisconsin has no financial relationships with a commercial interest.
- Umesh M. Mahantshetty, MD, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute has no financial relationships with a commercial interest.
- Eric W. Leung, MD, Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto has no financial relationships with a commercial interest.
- Michelle S. Ludwig, MD, PhD, MPH, Department of Radiation Oncology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine and Department of Radiation Oncology, Baylor College of Medicine has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.